Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis, remains a major global health challenge with rising prevalence and complex management needs. As part of the Global Gastroenterology, Liver Diseases & Hepatology Conference & Industry Expo, this dedicated IBD track brings together leading gastroenterologists, hepatologists, researchers, industry experts, and investors to explore cutting-edge advancements and collaborative solutions.
The session will highlight innovations in diagnostics, biologics, small molecules, microbiome-based therapies, precision medicine, and digital health transforming IBD care. Emphasis will be placed on translating research into real-world clinical practice and improving long-term patient outcomes.
This platform also fosters investment opportunities and industry partnerships, enabling collaboration between academia, healthcare providers, pharmaceutical companies, biotech startups, and technology innovators. Through keynote lectures, panel discussions, case-based sessions, and networking forums, participants will gain insights into emerging therapies, regulatory pathways, market trends, and commercialization strategies.
Join us to be part of a global dialogue shaping the future of IBD management—where science meets innovation, investment, and impactful partnerships to advance patient-centered care worldwide.
Sub Tracks Name: IBD Epidemiology and Global Burden, Pathophysiology of Crohn’s Disease, Ulcerative Colitis Clinical Updates, Genetics and IBD Susceptibility, Gut Microbiome and Dysbiosis, Immune Mechanisms in IBD, Biomarkers in IBD Diagnosis, Advanced Endoscopic Techniques, Imaging in IBD Management, Histopathology of IBD, Pediatric Inflammatory Bowel Disease, Geriatric IBD Care, Extraintestinal Manifestations of IBD, IBD and Liver Disorders, Primary Sclerosing Cholangitis in IBD, Novel Biologic Therapies, Small Molecule Drugs in IBD, Biosimilars and Treatment Optimization, Precision Medicine in IBD, Personalized Nutrition and Diet Therapy, Microbiota-Based Therapies, Fecal Microbiota Transplantation, Surgical Management of IBD, Post-Surgical Complications, IBD-Associated Colorectal Cancer, Cancer Surveillance in IBD, Pregnancy and Fertility in IBD, Psychological Impact of IBD, Quality of Life and Patient-Reported Outcomes, Digital Health and AI in IBD Care, Telemedicine in Gastroenterology, IBD Flare Prediction Models, Drug Safety and Pharmacovigilance, Clinical Trials and Real-World Evidence, Regulatory and Ethical Challenges, Health Economics and Cost-Effectiveness, Access to Care in Low-Resource Settings, Industry–Academia Collaborations, Investment Trends in IBD Therapeutics, Biotech Innovations in IBD, Medical Devices for IBD Management, Nutraceuticals and Complementary Therapies, Environmental Triggers of IBD, Infection Risk and Vaccination Strategies, Transition of Care from Pediatric to Adult IBD, Future Directions in IBD Research.
Keynote Points:
Growing global demand for OTC digestive remedies and self-care solutions
Rising consumer awareness of gut health and preventive digestive care
Diverse product categories: antacids, probiotics, enzymes, fiber supplements, herbal products
Increasing availability through pharmacies, e-commerce, and wellness stores
Opportunities for personalized and functional digestive health products
Potential for cross-promotions with lifestyle, wellness, and nutrition brands
Regulatory compliance and quality assurance as differentiating factors
Benefits:
High market growth due to recurring consumer demand for self-care products
Attractive ROI for innovative and branded OTC digestive solutions
Strong opportunity for brand building, customer loyalty, and direct-to-consumer engagement
Cross-industry partnerships with wellness, nutrition, and digital health platforms
Ability to leverage preventive healthcare trends and gut health awareness campaigns
Expands reach in both mature and emerging markets
WhatsApp: https://wa.me/+971551792927
Email: info-ucg@utilitarianconferences.com